FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

50 letters match. Newest first.

  1. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  2. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  3. Maria E. De La Torre Silva, M.D.

    Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.

    Medium
  4. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  5. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  6. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  7. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  8. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  9. Mark S. Dacey, M.D.

    FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.

    High risk
  10. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  11. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  12. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk
  13. Maria A. Carballosa, M.D.

    FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

    Medium
  14. Verdure Sciences, Inc.

    FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.

    High risk
  15. Ralph A. DeFronzo, M.D.

    FDA warns Dr. Ralph A. DeFronzo for enrolling ineligible subjects and failing to promptly report study changes to the IRB.

    High risk
  16. Mark J. Savant, M.D

    FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.

    High risk
  17. Peter Michael, M.D.

    FDA warns clinical investigator Peter Michael, M.D. that pediatric trial subjects received twice the protocol's maximum drug dose.

    High risk
  18. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  19. United Health Products, Inc.

    FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.

    High risk
  20. Nana Barseghian, M.D.

    FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.

    High risk
  21. Americo F. Padilla, M.D.

    FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.

    High risk
  22. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  23. Han C. Phan, M.D.

    FDA warns clinical investigator Dr. Han C. Phan over failure to follow a drug study’s protocol for required tests.

    Medium
  24. Richard W. Foltin, Ph.D.

    FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.

    High risk
  25. Konrad Rejdak, M.D., Ph.D.

    FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.

    Medium
  26. Massachusetts Institute of Technology MIT

    FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.

    Medium
  27. Kevin R. Bender, M.D./DBC Research Corporation

    Clinical investigator Kevin R. Bender failed to secure a controlled investigational drug, and 110 kits were stolen.

    High risk
  28. Bret R. Rutherford, M.D.

    FDA warned Dr. Bret R. Rutherford for enrolling ineligible patients in two drug studies by skipping required antidepressant washout.

    High risk
  29. New York State Psychiatric Institute IRB

    FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.

    High risk
  30. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

    High risk
  31. Anish S. Shah, M.D./Siyan Clinical Research

    FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.

    Medium
  32. Maria W. Greenwald, M.D.

    FDA warned Dr. Maria W. Greenwald over clinical trial violations involving investigational drugs, including ineligible subjects and inaccurate records.

    High risk
  33. Antonio E. Blanco, M.D./Vista Health Research, LLC

    FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

    High risk
  34. Luis Javier Pena-Hernandez, M.D., FCCP

    FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.

    High risk
  35. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  36. Mobeen Mazhar, M.D.

    FDA warned clinical investigator Dr. Mobeen Mazhar for enrolling ineligible subjects, missing safety reports, and consenting a subject late in drug trials.

    High risk
  37. Robert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics

    FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.

    High risk
  38. Maggie Jeffries, M.D. / Avanti Anesthesiology, LLC

    FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.

    High risk
  39. Larkin Community Hospital Institutional Review Board

    Larkin Community Hospital IRB cited for approving trials without required nonscientist member and incomplete records.

    Medium
  40. "David M. Lubeck, M.D./Arbor Centers for EyeCare

    FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.

    High risk
  41. Valley Biosystems

    FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.

    High risk
  42. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  43. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk
  44. Sabine S. Hazan, M.D.

    FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.

    High risk
  45. Vasyl Melnyk, M.D.

    FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.

    Medium
  46. Lauren R. Klein, MD, M.S.

    FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.

    High risk
  47. Jon B. Cole, MD

    FDA warns Dr. Jon B. Cole he ran two pre-hospital drug studies without required INDs, adding risks for pregnant women, children, and intoxicated patients.

    High risk
  48. RAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.

    FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.

    High risk
  49. Kaleido Biosciences, Inc.

    Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.

    High risk
  50. Evelyn Lopez-Brignoni, M.D.

    FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.

    High risk